Vertex Pharmaceuticals to Acquire ViaCyte Inc to Accelerate its Potentially Curative VX-880 Programs in Type 1 Diabetes

Vertex Pharmaceuticals and ViaCyte Inc are in the NEWS
Vertex Pharmaceuticals (VRTX) entered into a definitive agreement under which it will acquire ViaCyte, a private biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
From Vertex Pharmaceuticals and ViaCyte Inc
Reshma Kewalramani, M . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.